Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
Adult
Angiotensin-Converting Enzyme 2
Animals
Antibodies, Monoclonal
/ blood
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antibody Affinity
Antibody Specificity
Betacoronavirus
/ immunology
Binding Sites
COVID-19
Cell Line
Coronavirus Infections
/ immunology
Disease Models, Animal
Epitopes
Female
Humans
Immunization, Passive
Lung
/ virology
Male
Mesocricetus
Middle Aged
Neutralization Tests
Pandemics
/ prevention & control
Peptidyl-Dipeptidase A
/ metabolism
Pneumonia, Viral
/ immunology
Protein Domains
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ chemistry
Viral Load
Virus Replication
COVID-19 Serotherapy
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
21 08 2020
21 08 2020
Historique:
received:
12
05
2020
accepted:
11
06
2020
pubmed:
17
6
2020
medline:
2
9
2020
entrez:
17
6
2020
Statut:
ppublish
Résumé
Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-recovered participants, developed neutralization assays to investigate antibody responses, adapted our high-throughput antibody generation pipeline to rapidly screen more than 1800 antibodies, and established an animal model to test protection. We isolated potent neutralizing antibodies (nAbs) to two epitopes on the receptor binding domain (RBD) and to distinct non-RBD epitopes on the spike (S) protein. As indicated by maintained weight and low lung viral titers in treated animals, the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs also define protective epitopes to guide vaccine design.
Identifiants
pubmed: 32540903
pii: science.abc7520
doi: 10.1126/science.abc7520
pmc: PMC7299280
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Epitopes
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
956-963Subventions
Organisme : NIAID NIH HHS
ID : R01 AI132317
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007244
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI145762
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135995
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI073148
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007036
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Commun. 2015 Sep 15;6:8223
pubmed: 26370782
Nature. 2016 Mar 3;531(7592):118-21
pubmed: 26935699
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Adv Immunol. 2001;77:195-262
pubmed: 11293117
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6675-6685
pubmed: 32152119
Pediatrics. 1998 Sep;102(3 Pt 1):531-7
pubmed: 9738173
J Virol. 2005 Jan;79(1):503-11
pubmed: 15596843
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Cell Host Microbe. 2020 May 13;27(5):695-698
pubmed: 32407707
J Virol. 2004 Sep;78(17):9007-15
pubmed: 15308697
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Nat Rev Immunol. 2018 May;18(5):297-308
pubmed: 29379211
Cell. 2019 May 30;177(6):1566-1582.e17
pubmed: 31104840
Immunity. 2018 Feb 20;48(2):339-349.e5
pubmed: 29396163
J Virol. 2007 Mar;81(5):2418-28
pubmed: 17166901
Clin Infect Dis. 2020 Mar 26;:
pubmed: 32215622
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949
pubmed: 28096333
Microbiol Spectr. 2014 Dec;2(6):
pubmed: 26104444
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
Nucleic Acids Res. 2009 Jan;37(Database issue):D1006-12
pubmed: 18978023
Science. 2016 Mar 18;351(6279):1343-6
pubmed: 26917592